Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
Eslicarbazepine acetate, a third-generation antiepileptic drug (AED), has shown improved clinical response and safety in comparison to older generation AEDs for patients with partial-onset seizures. It is currently not known whether eslicarbazepine acetate is safe to use in patients with the acute h...
Saved in:
Main Authors: | Christopher D. Ma (Author), Herbert L. Bonkovsky (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of porphyrogenicity of drugs and chemicals in selected hepatic cell culture models through a fluorescence‐based screening assay
by: Christopher D. Ma, et al.
Published: (2022) -
Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy
by: Majeed CN, et al.
Published: (2022) -
Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Nav1.5 Channels
by: Theresa K. Leslie, et al.
Published: (2020) -
Social cognition and prefrontal cognitive function in patients with epilepsy treated with eslicarbazepine acetate
by: Laura Abraira, et al.
Published: (2017) -
Eslicarbazepine acetate: An efficacy and safety as an antiepileptic drug in clinical trials and open studies
by: Martyna Stefaniak, et al.
Published: (2022)